Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
SIGA Technologies Inc
NASDAQ SIGA
Data sourced from
and
and
SIGA Technologies Inc Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2024: USD 0.36
SIGA Technologies Inc Revenue Per Share is USD 0.36 for the Trailing 12 Months (TTM) ending March 31, 2024, a -4.13% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.
-
SIGA Technologies Inc Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 0.37, a -20.36% change year over year.
-
SIGA Technologies Inc Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 0.47, a 15.44% change year over year.
-
SIGA Technologies Inc Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 0.40, a 598.04% change year over year.
-
SIGA Technologies Inc Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 0.06, a -96.06% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: SIGA
| CEO | Dr. Phillip Louis Gomez III, M.D., Ph.D. |
| IPO Date | Sept. 9, 1997 |
| Location | United States |
| Headquarters | 31 East 62nd Street, New York, NY, United States, 10065 |
| Employees | 45 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Key trends
Similar companies
Catalent Inc
NA
NA
Phibro Animal Health Corporation
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email